Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.

[1]  A. Gavaldá,et al.  Discovery of substituted phenyl urea derivatives as novel long-acting β2-adrenoreceptor agonists. , 2011, Bioorganic & medicinal chemistry letters.

[2]  B. Cuenoud,et al.  A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. , 2010, Bioorganic & medicinal chemistry letters.

[3]  A. Schnapp,et al.  Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. , 2010, Bioorganic & medicinal chemistry letters.

[4]  M. Cazzola,et al.  Novel bronchodilators in asthma , 2010, Current opinion in pulmonary medicine.

[5]  A. Schnapp,et al.  Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists. , 2009, Bioorganic & medicinal chemistry letters.

[6]  A. Schnapp,et al.  Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action. , 2009, Bioorganic & medicinal chemistry letters.

[7]  I. McLay,et al.  Synthesis and Structure−Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups , 2009 .

[8]  Mark E Bunnage,et al.  The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists. , 2008, Bioorganic & medicinal chemistry letters.

[9]  Mark E Bunnage,et al.  The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD. , 2007, Bioorganic & medicinal chemistry letters.

[10]  Alan Daniel Brown,et al.  The discovery of long acting β2-adrenoreceptor agonists , 2007 .

[11]  J. Fozard,et al.  In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action , 2006, Journal of Pharmacology and Experimental Therapeutics.

[12]  B. Waldeck.  Beta-adrenoceptor agonists and asthma--100 years of development. , 2002, European journal of pharmacology.

[13]  H. Matthys.  Is There a Need for Another Inhalative β2-Agonist besides Formoterol in Patients with Asthma? , 2001, Respiration.

[14]  R C Brown,et al.  Dual D2-receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues. , 1998, Journal of medicinal chemistry.

[15]  J. Lötvall,et al.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[16]  R. Hammer,et al.  Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs. , 1997, European journal of pharmacology.

[17]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[18]  E. Corey,et al.  A new process for the enantioselective synthesis of chiral α-aryloxy- and α-hydroxy acids , 1992 .

[19]  G. Anderson.  Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.

[20]  D. Mathre,et al.  A practical enantioselective synthesis of .alpha.,.alpha.-diaryl-2-pyrrolidinemethanol. Preparation and chemistry of the corresponding oxazaborolidines , 1991 .